Transient Ischemic AttackNCT02669394

Reshaping the Path of Vascular Cognitive Impairment (VCI)

A study testing Resistance exercise training in people with Transient Ischemic Attack and Vascular Cognitive Impairment, run by University of British Columbia at 1 site in Canada.

Completed

Finished. The study has ended and is not enrolling. Results may be posted on the official record.

Official record

Search all trials

Trial summary

The investigators will conduct a proof-of-concept randomized controlled trial study to provide preliminary evidence of efficacy of a resistance exercise training program for maintaining white matter health and improving cognitive function in older adults with vascular cognitive impairment, defined as the presence of… Read more about this study

Who is it for?: Ages 55 years and older
Conditions the study is for: Transient Ischemic Attack, Vascular Cognitive Impairment, Subcortical Vascular Dementia
What is being tested?: Resistance exercise training
Type of treatment: Lifestyle or therapy programme
Could I receive a placebo?: No, everyone receives an active treatment
How many people: 91 participants
Where: 1 siteCanada
Study dates: 17 May 2016to 2 Jun 2022
Phase: Interventional
Are there results?: None posted in the registry

Key requirements

Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.

Ages 55 years and older
All sexes
No healthy volunteers
Adult, Older adult

Who may be able to join

The study will specifically recruit individuals who fulfill the diagnostic criteria for SIVCI -- the presence of both cognitive impairment and small vessel ischaemic disease.
Specifically, individuals must meet the following inclusion criteria:
Montreal Cognitive Assessment (MoCA) score less than 26 at screening;
MMSE score of = or > 20 at screening;
Community-dwelling;
Lives in Metro Vancouver;

Show all 12Show fewer

Able to comply with scheduled visits, treatment plan, and other trial procedures;
Must be able to read, write, and speak English in which psychometric tests are provided with acceptable visual and auditory acuity;
Stable on a fixed dose of cognitive medications (e.g., donepezil, galantamine, rivastigmine, memantine, etc.) that is not expected to change during the 12-month study period, or, if they are not on any of these medications, they are not expected to start them during the 12-month study period;
Provide a personally signed and dated informed consent document indicating that the individual (or a legally acceptable representative) has been informed of all pertinent aspects of the trial. In addition, an assent form will be provided at baseline and again at regular intervals;
Able to walk independently; and
Must be in sufficient health to participate in study's aerobic-based exercise training program. This will be based on medical history, vital signs, physical examination by study physicians, and written recommendation by family physician indicating individual's appropriateness to participate in an aerobic-based exercise training program.

Who cannot join

Absence of relevant small vessel ischaemic lesions on an existing brain computed tomography (CT) or MRI;
Diagnosed with another type of dementia (e.g., AD) or other neurological conditions (e.g., multiple sclerosis, Parkinson's disease, etc.) that affects cognition and mobility;
Diagnosed previously with a genetic cause of SIVCI (e.g., CADASIL);
At high risk for cardiac complications during exercise and/or unable to self-regulate activity or to understand recommended activity level (i.e., Class C of the American Heart Risk Stratification Criteria);
Participating in regular RT in the last six months;
Have clinically significant peripheral neuropathy or severe musculoskeletal or joint disease that impairs mobility;

Show all 9Show fewer

Taking medications that may negatively affect cognitive function, such as anticholinergics, including agents with pronounced anticholinergic properties (e.g., amitriptyline), major tranquilizers (typical and atypical antipsychotics), and anticonvulsants (e.g., gabapentin, valproic acid, etc.); or
Individual who plans to participate or is enrolled in a clinical drug trial concurrent to this study.
Unable to meet the specific scanning requirements of the UBC 3T MRI Research Centre. Specifically, we will exclude anyone with: pacemaker, brain aneurysm clip, cochlear implant, recent surgery or tattoos within the past 6 weeks, electrical stimulator for nerves or bones, implanted infusion pump, history of any eye injury involving metal fragments, artificial heart valve, orthopedic hardware, other metallic prostheses, coil, catheter or filter in any blood vessel, ear or eye implant, bullets, or other metallic fragments.

Trial locations and contacts

1 site in 1 country.

Canada1 site

University of British Columbia
Vancouver, British Columbia, V5Z 1M9

Other trials in Canada

About this study

Official title: Reshaping the Path of Vascular Cognitive Impairment With Resistance Training

Read the detailed description

A total of 88 adults with vascular cognitive impairment will be randomized to either a 12-month twice-weekly resistance training program or stretch and relaxation program. There will be three measurement sessions: baseline, 6 months (midpoint of intervention period), and 12 months (end of intervention period).

Conditions: Transient Ischemic Attack, Vascular Cognitive Impairment, Subcortical Vascular Dementia
Being tested: Resistance exercise training, Control: stretching and relaxation program
Medical subject headings: Ischemic Attack, Transient, Dementia, Vascular

What participants receive

What participants receive. In a randomised study each person is assigned to one group by chance.

Resistance exercise trainingBehavioural
Also called RT Program
Twelve months of twice-weekly resistance training program that will gradually progress in intensity. Each training session will be 60 minutes (10 minutes of warm-up, 40 minutes of training, and 10 minutes of cool-down).
Control: stretching and relaxation programBehavioural
Also called CON Program
Twelve months of twice-weekly stretching and relaxation program that includes stretches, deep breathing and relaxation techniques, general core control exercises, and general posture and health education. Each session will be 60 minutes.

Study groups in NCT02669394
Study group	Role	What they receive
Resistance Training (RT)	Experimental	The RT program will be a twice-weekly program. A pressurized air system and free weights will be used . The pressurized air system exercises will consist of biceps curls, triceps extension, seated row, latissmus dorsi pull downs, leg press, hamstring curls, and calf raises. Other exercises, with free weights, will include mini-squats, mini-lunges, and lunge walks. The intensity of the training stimulus will initially be at 50% to 60% of 1 repetition maximum (RM) as determined at week two, and progress to 75% to 85% of 1-RM at a work level of 6 to 8 repetitions (2 sets) by week four. The training stimulus will be increased using the 7 RM method. To meet the public health mandates of COVID-19, when it is necessary, training will occur at home, with the use of a set of resistance bands of various weights. Participants will be provided access to instructional videos either by YouTube or DVD. They will be called on a weekly basis to monitor progress and compliance. Receives: Behavioral: Resistance exercise training
Stretching and Relaxation (CON)	Active comparator	The CON program will be a twice-weekly program. The CON group will consist of stretching exercises, basic core-strength/kegal exercises, and relaxation techniques. Other than bodyweight, no additional loading (e.g., hand weights, resistance bands, etc.) will be applied to any of the exercises. To meet the public health mandates of COVID-19, when it is necessary, training will occur at home. Participants will be provided access to instructional videos either by YouTube or DVD. They will be called on a weekly basis to monitor progress and compliance. Receives: Behavioral: Control: stretching and relaxation program

What is being measured

The primary outcome is the main question the study is designed to answer.

Cognitive function as measured by Alzheimer's Disease Assessment Scale Cognitive Subscale Plus (ADAS-Plus)
ADAS-Cog 13 Plus additional cognitive tests
Measured: Baseline, 6 months, and 12 months
Change in white matter health as measured by total white matter lesion volume
White matter hyperintensity volume in mm3
Measured: Baseline to 12 months

Secondary outcomes (33)

Executive functions as measured by standard neuropsychological tests
Measured: Baseline, 6 months, and 12 months
Arterial stiffness as measured by carotid-femoral arterial pulse-wave velocity (PWV) (subset only)
Measured: Baseline and 12 months
Cardiometabolic risk factors as measured by blood panel (subset only)
Measured: Baseline, 6 months, and 12 months
Cardiometabolic risk factors as measured by body mass index
Measured: baseline, 6 months, and 12 months
Cardiometabolic risk factors as measured by waist to hip ratio
Measured: baseline, 6 months, and 12 months
Physiological falls risk as measured by the Physiological Profile Assessment
Measured: baseline, 6 months, and 12 months
Mobility and balance as measured by the Short Physical Performance Battery
Measured: baseline, 6 months, and 12 months
Mood as measured by the Center for Epidemiologic Studies Depression Scale (CES-D)
Measured: baseline, 6 months, and 12 months
Quality of life as measured by the Medical Outcomes Study Short Form-6D (SF-6D)
Measured: baseline, 6 months, and 12 months
White matter integrity as measured by diffusion tensor imaging
Measured: baseline and 12 months
Myelin plasticity as measured by multicomponent relaxation imaging
Measured: baseline and 12 months
Memory as measured by standard neuropsychological tests
Measured: baseline, 6 months, and 12 months
Upper body strength as measured by grip strength
Measured: baseline, 6 months, and 12 months
Lower body strength as measured by 30 sec sit to stand test
Measured: baseline, 6 months, and 12 months
Functional capacity as measured by 6 minute walk test
Measured: Baseline, 6 months, 12 months
Neurotrophic factors in blood: IGF-1, BDNF, VEGF (subset only)
Measured: Baseline, 6 months, 12 months
Self-reported physical activity as measured by the PASE questionnaire
Measured: Monthly
NIH Cognitive Toolbox
Measured: Baseline, 6 months, 12 months
Isokinetic strength of the lower limb (subset only)
Measured: Baseline, 6 months, 12 months
Functional connectivity using resting state fMRI (subset only)
Measured: Baseline and 12 months
Health resource utilization
Measured: Baseline and every 3 months
Prospective falls via monthly falls calendars
Measured: Monthly
Mobility using Timed up and Go Test
Measured: Baseline, 6 months, 12 months
Dual-task ability using dual-task timed up and go test
Measured: Baseline, 6 months, 12 months
Dual task gait using Gaitrite mat (subset only)
Measured: Baseline, 6 months, 12 months
Cognitive function using ADAS-Cog 13
Measured: Baseline, 6 months, 12 months
Dominant quad isometric strength using a strain gauge
Measured: Baseline, 6 months, 12 months
Hypothalamic-pituitary-adrenal axis activity using saliva samples (i.e., cortisol) (subset only)
Measured: Baseline, 6 months, 12 months
Regional brain volumes using structural MRI
Measured: Baseline and 12 months
Selected Pro- and anti-inflammatory cytokines in blood (subset only)
IFN-alpha, IL-1 alpha, IL-4, IL-6, IL-10, IL-12p70, IL-13, IL-17, TNF-alpha, Rantes, CXCL1, IL-18, TGF-B
Measured: Baseline, 6 months, and 12 months
Telomere Length (subset only)
Measured: Baseline, 6 months, and 12 months
Sleep quality as measured by MW8
Measured: Baseline, 6 months, and 12 months
Brain Age as derived from structural scans
Brain Age
Measured: Baseline and 12 months

Timeline

From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.

17 May 20162 Jun 2022

First posted1 Feb 2016 (estimated)
Study start17 May 2016
Primary completion2 Jun 2022
Study completion2 Jun 2022

Resources

Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
Publications (6)Papers the sponsor has linked to this study.
Other trials for Transient Ischemic AttackStudies of the same condition, open and under way.
More trials run by University of British ColumbiaThe sponsor's other registered studies.
What the trial phases meanHow a treatment moves from first tests in people to approval.

More details

For doctors and researchers: how the study is designed, who runs it, and its registry IDs.

Study design

Study type: Interventional
Phase: Phase N/A
Primary purpose: Treatment
Allocation: Randomised
Intervention model: Parallel groups
Masking: Single blind
Who is masked: Participant
Enrolment: 91 participants (actual)

IDs, dates and publications

ClinicalTrials.gov ID: NCT02669394
Sponsor's protocol ID: H15-00972
Status last verified: Mar 2026
First submitted: 14 Jan 2016
Last updated: 17 Mar 2026
Results posted: No
Data monitoring committee: Yes
Individual data sharing: No

Publications

Boa Sorte Silva NC, Tam RC, Alkeridy WA, Lam K, Dao E, Barha CK, Falck RS, Hsu CL, Hsiung GR, Madden KM, Field TS, Liu-Ambrose T. Exercise and white matter hyperintensities: a randomized clinical trial. Brain Commun. 2026 Oct 8;8(5):fcag381. doi: 10.1093/braincomms/fcag381. eCollection 2026.
PubMed 42948654
Falck RS, Barha CK, Stein RG, Grant S, Bullock A, Madden KM, Davis JC, Tam R, Liu-Ambrose T. Resistance training and depressive symptoms in subcortical vascular cognitive impairment: secondary results of a randomised clinical trial. Br J Sports Med. 2026 Sep 3:bjsports-2026-112111. doi: 10.1136/bjsports-2026-112111. Online ahead of print.
PubMed 42692806
Gu Y, Hsu CL, Boa Sorte Silva NC, Tam RC, Alkeridy WA, Lam K, Liu-Ambrose T. Probing cognitive reserve with resting state functional connectivity in subcortical ischemic vascular cognitive impairment. J Alzheimers Dis Rep. 2026 Jan 6;10:25424823251409395. doi: 10.1177/25424823251409395. eCollection 2026 Jan-Dec.
PubMed 41929984
Liu-Ambrose T, Falck RS, Dao E, Crockett RA, Barha CK, Silva NCBS, Alkeridy WA, Best JR, Hsiung GR, Field TS, Madden KM, Davis JC, Ten Brinke LF, Tam RC. Resistance training and subcortical vascular cognitive impairment: A 12-month randomized trial. Alzheimers Dement. 2026 Mar;22(3):e71245. doi: 10.1002/alz.71245.
PubMed 41795685
Balbim GM, Boa Sorte Silva NC, Falck RS, Kramer AF, Voss MW, Liu-Ambrose T. 24-hour activity cycle behaviors and gray matter volume in mild cognitive impairment. Alzheimers Dement. 2025 Jul;21(7):e70496. doi: 10.1002/alz.70496.
PubMed 40693459
Liu-Ambrose T, Dao E, Crockett RA, Barha CK, Falck RS, Best JR, Hsiung GR, Field TS, Madden KM, Alkeridy WA, Boa Sorte Silva NC, Davis JC, Ten Brinke LF, Doherty S, Tam RC. Reshaping the path of vascular cognitive impairment with resistance training: a study protocol for a randomized controlled trial. Trials. 2021 Mar 18;22(1):217. doi: 10.1186/s13063-021-05156-1.
PubMed 33736706

Want to know more?

The sponsor has not listed a contact. The official record may have more details.

Talk to your doctor first and take this page with you. Only the study team can confirm whether you can join.

Questions to ask the study team

What is the study trying to find out?
What would I need to do, and how often would I visit?
Could I receive a placebo instead of the treatment?
What are the possible risks and benefits for me?
Will it cost me anything? Are travel or time paid for?
Can I keep seeing my own doctor during the study?
What happens when the study ends?

See locations

Active, not recruitingObservational study
Symptomatic Carotid Outcomes Registry
Carotid Stenosis, Ischemic Stroke
Not yet recruitingObservational study
Integrating Wearable Monitoring and Clinical Data for Stroke Early Warning
Stroke, Ischemic Stroke
Not yet recruitingObservational study
PET-MR Imaging of Natriuretic Peptide Receptor C (NPR-C) in Carotid Atherosclerosis With 64Cu-NODAGA-CANF (Multisite)
Carotid Atherosclerosis, Carotid Artery Stenosis Asymptomatic
Not yet recruitingPhase 3
Upfront Lipid-Lowering Therapy With Statins Combined With Hybutimibe in Patients With Acute Ischemic Stroke or Transient Ischemic Attack.
Ischemia Stroke, TIA (Transient Ischemic Attack)
Recruiting
Understanding and Enhancing Human Health and Movement
Spinal Cord Injury, Stroke (CVA) or Transient Ischemic Attack

All Transient Ischemic Attack trials

Study at a glance

From the registry record, last updated by the sponsor on 17 Mar 2026. Recruitment status is as the sponsor reported it: confirm with the study team.

Official title: Reshaping the Path of Vascular Cognitive Impairment With Resistance Training
ClinicalTrials.gov ID: NCT02669394
Acronym / sponsor ID: H15-00972
Conditions: Transient Ischemic Attack, Vascular Cognitive Impairment, Subcortical Vascular Dementia
Study type: Interventional
Recruitment status: Completed
Enrolment: 91 participants (actual)
Lead sponsor: University of British ColumbiaUniversity, hospital or other
Study start: 17 May 2016 (actual)
Primary completion: 2 Jun 2022 (actual)
Study completion: 2 Jun 2022 (actual)
First posted: 1 Feb 2016 (estimated)
Results: Not posted in the source record

Clinical summary

The research question as the sponsor registered it. This describes what the study plans to test, not what it found.

Detailed description

Study design

Primary purpose: Treatment
Allocation: Randomised
Intervention model: Parallel groups
Masking: Single blind (participant)
Number of arms: 2

Arm	Type	Receives
Resistance Training (RT)	Experimental	Behavioral: Resistance exercise trainingThe RT program will be a twice-weekly program. A pressurized air system and free weights will be used . The pressurized air system exercises will consist of biceps curls, triceps extension, seated row, latissmus dorsi pull downs, leg press, hamstring curls, and calf raises. Other exercises, with free weights, will include mini-squats, mini-lunges, and lunge walks. The intensity of the training stimulus will initially be at 50% to 60% of 1 repetition maximum (RM) as determined at week two, and progress to 75% to 85% of 1-RM at a work level of 6 to 8 repetitions (2 sets) by week four. The training stimulus will be increased using the 7 RM method. To meet the public health mandates of COVID-19, when it is necessary, training will occur at home, with the use of a set of resistance bands of various weights. Participants will be provided access to instructional videos either by YouTube or DVD. They will be called on a weekly basis to monitor progress and compliance.
Stretching and Relaxation (CON)	Active comparator	Behavioral: Control: stretching and relaxation programThe CON program will be a twice-weekly program. The CON group will consist of stretching exercises, basic core-strength/kegal exercises, and relaxation techniques. Other than bodyweight, no additional loading (e.g., hand weights, resistance bands, etc.) will be applied to any of the exercises. To meet the public health mandates of COVID-19, when it is necessary, training will occur at home. Participants will be provided access to instructional videos either by YouTube or DVD. They will be called on a weekly basis to monitor progress and compliance.

Who may qualify

Ages: 55 years and older
Sex: All
Healthy volunteers: Not accepted
Age groups: Adult, Older adult

Key inclusion criteria (12 listed)

The study will specifically recruit individuals who fulfill the diagnostic criteria for SIVCI -- the presence of both cognitive impairment and small vessel ischaemic disease.
Montreal Cognitive Assessment (MoCA) score less than 26 at screening;
MMSE score of = or > 20 at screening;
Community-dwelling;
Lives in Metro Vancouver;

Key exclusion criteria (9 listed)

Absence of relevant small vessel ischaemic lesions on an existing brain computed tomography (CT) or MRI;
Diagnosed with another type of dementia (e.g., AD) or other neurological conditions (e.g., multiple sclerosis, Parkinson's disease, etc.) that affects cognition and mobility;
Diagnosed previously with a genetic cause of SIVCI (e.g., CADASIL);
At high risk for cardiac complications during exercise and/or unable to self-regulate activity or to understand recommended activity level (i.e., Class C of the American Heart Risk Stratification Criteria);
Participating in regular RT in the last six months;

Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.

Interventions

Intervention	Type	Arms
Resistance exercise trainingAlso: RT ProgramTwelve months of twice-weekly resistance training program that will gradually progress in intensity. Each training session will be 60 minutes (10 minutes of warm-up, 40 minutes of training, and 10 minutes of cool-down).	Behavioural	Resistance Training (RT)
Control: stretching and relaxation programAlso: CON ProgramTwelve months of twice-weekly stretching and relaxation program that includes stretches, deep breathing and relaxation techniques, general core control exercises, and general posture and health education. Each session will be 60 minutes.	Behavioural	Stretching and Relaxation (CON)

Primary outcome

Cognitive function as measured by Alzheimer's Disease Assessment Scale Cognitive Subscale Plus (ADAS-Plus)
Time frame: Baseline, 6 months, and 12 months
ADAS-Cog 13 Plus additional cognitive tests
Change in white matter health as measured by total white matter lesion volume
Time frame: Baseline to 12 months
White matter hyperintensity volume in mm3

33 secondary outcomes

Executive functions as measured by standard neuropsychological tests
Time frame: Baseline, 6 months, and 12 months
Arterial stiffness as measured by carotid-femoral arterial pulse-wave velocity (PWV) (subset only)
Time frame: Baseline and 12 months
Cardiometabolic risk factors as measured by blood panel (subset only)
Time frame: Baseline, 6 months, and 12 months
Cardiometabolic risk factors as measured by body mass index
Time frame: baseline, 6 months, and 12 months
Cardiometabolic risk factors as measured by waist to hip ratio
Time frame: baseline, 6 months, and 12 months
Physiological falls risk as measured by the Physiological Profile Assessment
Time frame: baseline, 6 months, and 12 months
Mobility and balance as measured by the Short Physical Performance Battery
Time frame: baseline, 6 months, and 12 months
Mood as measured by the Center for Epidemiologic Studies Depression Scale (CES-D)
Time frame: baseline, 6 months, and 12 months
Quality of life as measured by the Medical Outcomes Study Short Form-6D (SF-6D)
Time frame: baseline, 6 months, and 12 months
White matter integrity as measured by diffusion tensor imaging
Time frame: baseline and 12 months
Myelin plasticity as measured by multicomponent relaxation imaging
Time frame: baseline and 12 months
Memory as measured by standard neuropsychological tests
Time frame: baseline, 6 months, and 12 months
Upper body strength as measured by grip strength
Time frame: baseline, 6 months, and 12 months
Lower body strength as measured by 30 sec sit to stand test
Time frame: baseline, 6 months, and 12 months
Functional capacity as measured by 6 minute walk test
Time frame: Baseline, 6 months, 12 months
Neurotrophic factors in blood: IGF-1, BDNF, VEGF (subset only)
Time frame: Baseline, 6 months, 12 months
Self-reported physical activity as measured by the PASE questionnaire
Time frame: Monthly
NIH Cognitive Toolbox
Time frame: Baseline, 6 months, 12 months
Isokinetic strength of the lower limb (subset only)
Time frame: Baseline, 6 months, 12 months
Functional connectivity using resting state fMRI (subset only)
Time frame: Baseline and 12 months
Health resource utilization
Time frame: Baseline and every 3 months
Prospective falls via monthly falls calendars
Time frame: Monthly
Mobility using Timed up and Go Test
Time frame: Baseline, 6 months, 12 months
Dual-task ability using dual-task timed up and go test
Time frame: Baseline, 6 months, 12 months
Dual task gait using Gaitrite mat (subset only)
Time frame: Baseline, 6 months, 12 months
Cognitive function using ADAS-Cog 13
Time frame: Baseline, 6 months, 12 months
Dominant quad isometric strength using a strain gauge
Time frame: Baseline, 6 months, 12 months
Hypothalamic-pituitary-adrenal axis activity using saliva samples (i.e., cortisol) (subset only)
Time frame: Baseline, 6 months, 12 months
Regional brain volumes using structural MRI
Time frame: Baseline and 12 months
Selected Pro- and anti-inflammatory cytokines in blood (subset only)
Time frame: Baseline, 6 months, and 12 months
Telomere Length (subset only)
Time frame: Baseline, 6 months, and 12 months
Sleep quality as measured by MW8
Time frame: Baseline, 6 months, and 12 months
Brain Age as derived from structural scans
Time frame: Baseline and 12 months

Results and safety

The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.

Research links

Official record on ClinicalTrials.govLast updated by the sponsor 17 Mar 2026.
Derived from this study: PubMed 42948654Boa Sorte Silva NC, Tam RC, Alkeridy WA, Lam K, Dao E, Barha CK, Falck RS, Hsu CL, Hsiung GR, Madden KM, Field TS, Liu-Ambrose T. Exercise and white matter hyperintensities: a randomized clinical trial. Brain Commun. 2026 Oct 8;8(5):fcag381. doi: 10.1093/braincomms/fcag381. eCollection 2026.
Derived from this study: PubMed 42692806Falck RS, Barha CK, Stein RG, Grant S, Bullock A, Madden KM, Davis JC, Tam R, Liu-Ambrose T. Resistance training and depressive symptoms in subcortical vascular cognitive impairment: secondary results of a randomised clinical trial. Br J Sports Med. 2026 Sep 3:bjsports-2026-112111. doi: 10.1136/bjsports-2026-112111. Online ahead of print.
Derived from this study: PubMed 41929984Gu Y, Hsu CL, Boa Sorte Silva NC, Tam RC, Alkeridy WA, Lam K, Liu-Ambrose T. Probing cognitive reserve with resting state functional connectivity in subcortical ischemic vascular cognitive impairment. J Alzheimers Dis Rep. 2026 Jan 6;10:25424823251409395. doi: 10.1177/25424823251409395. eCollection 2026 Jan-Dec.
Derived from this study: PubMed 41795685Liu-Ambrose T, Falck RS, Dao E, Crockett RA, Barha CK, Silva NCBS, Alkeridy WA, Best JR, Hsiung GR, Field TS, Madden KM, Davis JC, Ten Brinke LF, Tam RC. Resistance training and subcortical vascular cognitive impairment: A 12-month randomized trial. Alzheimers Dement. 2026 Mar;22(3):e71245. doi: 10.1002/alz.71245.
Derived from this study: PubMed 40693459Balbim GM, Boa Sorte Silva NC, Falck RS, Kramer AF, Voss MW, Liu-Ambrose T. 24-hour activity cycle behaviors and gray matter volume in mild cognitive impairment. Alzheimers Dement. 2025 Jul;21(7):e70496. doi: 10.1002/alz.70496.
Derived from this study: PubMed 33736706Liu-Ambrose T, Dao E, Crockett RA, Barha CK, Falck RS, Best JR, Hsiung GR, Field TS, Madden KM, Alkeridy WA, Boa Sorte Silva NC, Davis JC, Ten Brinke LF, Doherty S, Tam RC. Reshaping the path of vascular cognitive impairment with resistance training: a study protocol for a randomized controlled trial. Trials. 2021 Mar 18;22(1):217. doi: 10.1186/s13063-021-05156-1.
Individual participant dataSharing planned: No

Related trials for Transient Ischemic Attack

Active, not recruitingObservational study
Symptomatic Carotid Outcomes Registry
Carotid Stenosis, Ischemic Stroke
Not yet recruitingObservational study
Integrating Wearable Monitoring and Clinical Data for Stroke Early Warning
Stroke, Ischemic Stroke
Not yet recruitingObservational study
PET-MR Imaging of Natriuretic Peptide Receptor C (NPR-C) in Carotid Atherosclerosis With 64Cu-NODAGA-CANF (Multisite)
Carotid Atherosclerosis, Carotid Artery Stenosis Asymptomatic
Not yet recruitingPhase 3
Upfront Lipid-Lowering Therapy With Statins Combined With Hybutimibe in Patients With Acute Ischemic Stroke or Transient Ischemic Attack.
Ischemia Stroke, TIA (Transient Ischemic Attack)
Recruiting
Understanding and Enhancing Human Health and Movement
Spinal Cord Injury, Stroke (CVA) or Transient Ischemic Attack

Referral and contact

AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part. This study is not recruiting at the moment.

Teresa Liu-Ambrose, PhD, PT principal investigator

University of British Columbia

John Best, PhD principal investigator

University of British Columbia

Jennifer Davis, PhD principal investigator

University of British Columbia

1 site in 1 country: see every site and its status.

Questions about this trial

What is this clinical trial studying?

A study testing Resistance exercise training in people with Transient Ischemic Attack and Vascular Cognitive Impairment, run by University of British Columbia at 1 site in Canada.

The full registered description is in the About this study section and the official record.

Who may be eligible to take part?

The sponsor lists 12 inclusion and 9 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.

Is this clinical trial currently recruiting?

The record says: finished, as of the sponsor's last update on 17 Mar 2026. Status can change between updates, so confirm with the study contact before making plans.

Where is the study taking place?

The record lists 1 site in Canada. Whether a site is taking part right now should be confirmed with that site. See every site.

What are the possible benefits and risks?

They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.

Are results available for this study?

The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.

How can a doctor refer a patient or contact the research team?

The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.

What does the primary outcome measure?

Cognitive function as measured by Alzheimer's Disease Assessment Scale Cognitive Subscale Plus (ADAS-Plus) (time frame: Baseline, 6 months, and 12 months). The study lists 2 primary outcomes in all. It is what the study was designed to measure, not a finding.

Where can I read the original study information?

On the ClinicalTrials.gov record for NCT02669394, which also lists 6 linked publications.

Does a listing mean the treatment is approved or proven to work?

No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.

How often is this information updated?

AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 17 Mar 2026.